Section Arrow
GALT.NASDAQ
- Galectin Therapeutics
Quotes are at least 15-min delayed:2024/12/24 13:16 EST
Last
 0.8406
-0.0495 (-5.56%)
Day High 
0.88 
Prev. Close
0.8901 
1-M High
2.99 
Volume 
1.69M 
Bid
0.8227
Ask
0.852
Day Low
0.762 
Open
0.88 
1-M Low
0.726041 
Market Cap 
55.86M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.84 
20-SMA 2.17 
50-SMA 2.48 
52-W High 4.2684 
52-W Low 0.726041 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.73/-0.93
Enterprise Value
127.61M
Balance Sheet
Book Value Per Share
-1.51
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TNXPTonix Pharmaceuticals Holding Corp.0.3853-0.0178-4.42%-- 
CMNDClearmind Medicine1.72+0.5+40.98%0.16PE
CEROCERo Therapeutics Holdings0.0623+0.0118+23.37%-- 
ATNF180 Life Sciences Corp2.9+1.03+55.08%0.23PE
RXRXRecursion Pharmaceuticals7.24+0.25+3.58%-- 
Quotes are at least 15-min delayed:2024/12/24 13:16 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.